Anavex Life Sciences earnings release, July 30, 2026

Anavex Life Sciences Corp. (AVXL) · Form 8-K, Item 2.02 · Filed · SEC filing

Anavex

Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update

Establishing

Disciplined, Data-Driven Strategy with Focus on FDA Engagement for Alzheimer’s Disease

New York, NY, July 30, 2026

- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) diseases with high unmet medical needs, today reported preliminary financial results for its fiscal second quarter ended March 31, 2026. The Company’s primary focus is on advancing its lead compound

ANAVEX®2-73

(blarcamesine) in the Company’s clinical program for the treatment of mild cognitive impairment (“MCI”) due to Alzheimer’s disease (“AD”) and mild AD (collectively known as “early AD”), and for Rett syndrome and Fragile X syndrome, both of which are neurodevelopmental rare diseases.

“Anavex remains firmly committed to our lead candidate oral blarcamesine

(ANAVEX®2-73) for patients with Alzheimer’s disease, and we are prioritizing engagement with the U.S. FDA to align on a clear, data-driven regulatory and clinical development strategy,” stated Terrie Kellmeyer, PhD,

Interim Chief Executive Officer. “A qualified data-driven approach will guide every decision we make. I have spent nearly three decades building and leading clinical and regulatory functions in drug development, and I’m bringing that experience to bear every day as we implement a disciplined regulatory strategy and build the right foundation for our programs. We are committed to advancing blarcamesine towards a clear regulatory path. I also want to recognize our employees, who have continued to show up for the patients who are counting on us, and the patients and families living with Alzheimer’s disease, Rett syndrome and Fragile X, who are depending on us to continue this important work on these urgent unmet medical needs. We are continuing to execute on the mission of developing targeted, orally delivered therapies for a specific range of CNS related diseases.”

Business Update & Anticipated

Upcoming Milestones

Alzheimer’s Disease

Program

Rett Syndrome Program

Fragile X Syndrome Program

Nasdaq Compliance

Preliminary Fiscal Second Quarter

2026 Highlights

The financial results in this press release are preliminary and subject to completion of the Company’s financial closing procedures. Actual results may vary materially from these preliminary financial results due to the completion of the Company’s financial closing procedures and other developments or information that may arise between now and the time of the finalization of the Company’s financial results for three and six months ended March 31, 2026.

Preliminary cash and cash equivalents were $127.4 million as of March 31, 2026, compared to $102.6 million as of September 30, 2025. The Company expects the cash balance at the end of the second fiscal quarter of 2026 to fund operations into mid-to-late fiscal 2028.

Preliminary general and administrative expenses were $2.3 million for the second fiscal quarter of 2026 compared to $2.6 million for the second fiscal quarter of 2025. The decrease was primarily related to a decrease in legal and professional fees over the comparable period.

Preliminary research and development expenses were $4.2 million for the second fiscal quarter of 2026 compared to $9.9 million for the second fiscal quarter of 2025. The decrease was primarily attributable to the completion of the

ANAVEX® 3-71 clinical trial for schizophrenia and a decrease in clinical manufacturing activities over the comparable period.

Preliminary Net loss for the second fiscal quarter of 2026 was $5.3 million, or $0.06 per share, compared to a net loss of $11.2 million, or $0.13 per share, for the second fiscal quarter of 2025.

About Anavex Life Sciences

Corp.

Anavex Life Sciences

Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company engaged in the development of novel therapeutics for the treatment of central nervous system (“CNS”) diseases with high unmet medical need. Further information is available at www.anavex.com.

Financial statements

Income Statement

Three months ended March 31, — ir@anavexcorp.com

Three months ended March 31, – 2026Three months ended March 31, – 2025
Operating ExpensesGeneral and administrative2,2922,621
Operating ExpensesResearch and development4,1929,892
Operating ExpensesTotal operating expenses6,48412,513
Operating ExpensesOperating loss-6,484-12,513
Other incomeResearch and development incentive income2796
Other incomeInterest income, net1,0611,210
Other incomeForeign exchange gain (loss)5811
Other incomeTotal other income, net1,1461,317
Other incomeNet loss before provision for income taxes-5,338-11,196
Other incomeNet loss and comprehensive loss-5,338-11,196
Net loss per shareBasic and diluted-0.06-0.13
Weighted average number of shares outstandingBasic and diluted92,675,75385,073,769

Income Statement

Six months ended March 31,

Six months ended March 31, – 2026Six months ended March 31, – 2025
Operating ExpensesGeneral and administrative4,4175,767
Operating ExpensesResearch and development8,84920,338
Operating ExpensesTotal operating expenses13,26626,105
Operating ExpensesOperating loss-13,266-26,105
Other incomeGrant income12
Other incomeResearch and development incentive income60508
Other incomeInterest income, net2,1402,604
Other incomeForeign exchange gain (loss)65-326
Other incomeTotal other income, net2,2652,798
Other incomeNet loss before provision for income taxes-11,001-23,307
Other incomeIncome tax expense, current-18
Other incomeNet loss and comprehensive loss-11,019-23,307
Net loss per shareBasic and diluted-0.12-0.27
Weighted average number of shares outstandingBasic and diluted90,832,57184,938,400

Balance Sheet

Anavex Life Sciences Corp. (in thousands, except share and per share amounts)

Anavex Life Sciences Corp. – Preliminary Condensed Consolidated Interim Balance Sheets[3] – March 31, 2026 – (unaudited)Anavex Life Sciences Corp. – Preliminary Condensed Consolidated Interim Balance Sheets[3] – September 30, 2025
CurrentCash and cash equivalents127,422102,577
CurrentIncentive and tax receivables932809
CurrentPrepaid expenses and other current assets412429
CurrentTotal Assets128,766103,815
Current LiabilitiesAccounts payable2,5204,249
Current LiabilitiesAccrued liabilities3,7343,892
Current LiabilitiesDeferred grant income805805
Current LiabilitiesTotal Liabilities7,0598,946
Current LiabilitiesCapital Stock9387
Current LiabilitiesAdditional paid-in capital515,081477,230
Current LiabilitiesAccumulated deficit-393,467-382,448
Current LiabilitiesTotal Stockholders’ Equity121,70794,869
Current LiabilitiesTotal Liabilities and Stockholders’ Equity128,766103,815
Full release

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements relating to the Company’s preliminary financial results for the second quarter of 2026; the Company’s plans to prioritize engagement with the U.S. FDA to align on a clear, data-driven regulatory and clinical development strategy; the Company’s plans to continue to execute on its mission of developing targeted, orally delivered therapies for a specific range of CNS-related diseases; the timing, progress and results of advancement of

ANAVEX®2-73 in clinical programs for the treatment of early Alzheimer’s,

Rett syndrome and Fragile X syndrome; the Company’s plans to align with the FDA on a U.S. clinical development strategy for early

Alzheimer’s disease, align on a Phase 3 protocol for Rett syndrome in both adult and pediatric patients, and align on a clinical development strategy for the Fragile X clinical program; and the Company’s expectations regarding its cash runway. These statements are based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such forward-looking statements due to various factors, including, but not limited to, risks related to the Company’s failure to timely file its Form 10-Q for the quarterly period ended March 31, 2026 and the Company’s ability to regain compliance with Nasdaq Listing Rule 5250(c)(1); that actual financial results may vary materially from the preliminary... (truncated)ess release; volatility in the Company’s stock price and the market in general; the Company’s ability to raise additional capital; Fast Track designation that the Company has received or may seek out may not actually lead to a faster

FDA review and approval process; the Company may be unable to maintain any benefits associated with orphan drug designation, including market exclusivity; undesirable side effects caused by the Company’s product candidates; the Company’s ability to attract and retain highly qualified personnel; the Company’s ability to obtain the support of qualified scientific collaborators; the Company’s reliance on third parties; the Company’s ability to obtain and maintain sufficient intellectual property protection for its product candidates; the Company’s ability to defend against claims of intellectual property infringement; the Company’s ability to compete in the highly competitive biotechnology and pharmaceutical industries; and other risks and uncertainties set forth in the Company’s

Annual Report on Form 10-K for the fiscal year ended September 30, 2025, and subsequent filings and furnishings with the Securities and

Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof except as required by law.

Investor Relations & Media

Contact:

SCR Partners, LLC

Alex Arzeno

Tel: 203-550-3972

Email: alex@scr-ir.com

Tripp Sullivan

Tel: 615-942-7077

Email: tsullivan@scr-ir.com

Company Contact:

Sandra Boenisch

Principal Financial Officer

Anavex Life Sciences Corp.

Tel: 1-844-689-3939

Email: ir@anavexcorp.com

[1]

The financial results in this press release are preliminary and subject to completion of the Company’s financial closing procedures.

Actual results may vary materially from these preliminary financial results due to the completion of the Company’s financial closing procedures and other developments or information that may arise between now and the time of the finalization of the Company’s financial results for three and six months ended March 31, 2026.

[2]

The financial results in this press release are preliminary and subject to completion of the Company’s financial closing procedures.

Actual results may vary materially from these preliminary financial results due to the completion of the Company’s financial closing procedures and other developments or information that may arise between now and the time of the finalization of the Company’s financial results for three and six months ended March 31, 2026.

[3]

The financial results in this press release are preliminary and subject to completion of the Company’s financial closing procedures.

Actual results may vary materially from these preliminary financial results due to the completion of the Company’s financial closing procedures and other developments or information that may arise between now and the time of the finalization of the Company’s financial results for three and six months ended March 31, 2026.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Anavex Life Sciences earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.